AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ: AMRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.80
+0.51% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.18
P/S ratio
1.35x
EPS (TTM)
$0.22
Dividend yield
—
52W range
$7 – $15
Volume
1.9M
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+31.2%
Last 4 quarters
Revenue YoY growth
+11.5%
Most recent quarter
EPS YoY growth
+75.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.0%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-5.0%
2026-02-27
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-27 | $0.21 | +16.2% | $14.49 | $13.77 | -5.0% |
| 2025-10-30 | $0.17 | +21.4% | $10.43 | $10.82 | +3.7% |
| 2025-08-05 | $0.25 | +47.1% | $7.96 | $8.05 | +1.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.18 | $0.21 | +16.2% | $814.32M | +11.5% |
| 2025-09-30 | $0.14 | $0.17 | +21.4% | $784.51M | +11.7% |
| 2025-06-30 | $0.17 | $0.25 | +47.1% | $724.51M | +3.2% |
| 2025-03-31 | $0.15 | $0.21 | +40.0% | $695.42M | +5.5% |
| 2024-12-31 | $0.15 | $0.12 | -20.0% | $730.52M | +18.4% |
| 2024-09-30 | $0.13 | $0.16 | +23.1% | $702.47M | +13.3% |
| 2024-06-30 | $0.14 | $0.16 | +14.3% | $701.78M | +17.1% |
| 2024-03-31 | $0.09 | $0.14 | +55.6% | $659.19M | — |
| 2023-12-31 | $0.09 | $0.14 | +55.6% | $616.98M | — |
| 2023-09-30 | $0.13 | $0.19 | +46.2% | $620.04M | — |
| 2023-06-30 | $0.11 | $0.19 | +72.7% | $599.05M | — |
Frequently asked questions
Has Amneal Pharmaceuticals, Inc. Class A Common Stock beaten earnings estimates?
Amneal Pharmaceuticals, Inc. Class A Common Stock has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +31.2% over the last 4 quarters.
How does AMRX stock react to earnings?
AMRX stock has moved an average of -0.0% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's revenue growth rate?
Amneal Pharmaceuticals, Inc. Class A Common Stock reported year-over-year revenue growth of +11.5% in its most recent quarter, with EPS growing +75.0% year-over-year.